CN109574809A - 一种羟基取代的菲类衍生物的合成方法 - Google Patents

一种羟基取代的菲类衍生物的合成方法 Download PDF

Info

Publication number
CN109574809A
CN109574809A CN201910044311.0A CN201910044311A CN109574809A CN 109574809 A CN109574809 A CN 109574809A CN 201910044311 A CN201910044311 A CN 201910044311A CN 109574809 A CN109574809 A CN 109574809A
Authority
CN
China
Prior art keywords
replaces
nmr
phenanthrene derivatives
hydroxyl
synthetic method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910044311.0A
Other languages
English (en)
Other versions
CN109574809B (zh
Inventor
宋恭华
王佳毅
张娟
彭延庆
夏琦
吴国栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China University of Science and Technology
Original Assignee
East China University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China University of Science and Technology filed Critical East China University of Science and Technology
Priority to CN201910044311.0A priority Critical patent/CN109574809B/zh
Publication of CN109574809A publication Critical patent/CN109574809A/zh
Application granted granted Critical
Publication of CN109574809B publication Critical patent/CN109574809B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0215Sulfur-containing compounds
    • B01J31/0225Sulfur-containing compounds comprising sulfonic acid groups or the corresponding salts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/18Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及一种羟基取代的菲类衍生物的合成方法,羟基取代的菲类衍生物是以2‑羧甲基联苯类化合物为原料,在催化剂的作用下反应而成,催化剂包括三氟甲磺酸或五氧化二磷中的一种或两种。与现有技术相比,本发明合成方法具有催化剂价廉易得、官能团普适性好、操作简便、反应时间短、反应收率高、反应条件温和等优点。

Description

一种羟基取代的菲类衍生物的合成方法
技术领域
本发明属于有机合成技术领域,涉及一种羟基取代的菲类衍生物的合成方法。
背景技术
羟基取代的菲类衍生物是一类重要的多环芳烃化合物,广泛存在于天然物质中,具有重要的生物、药物活性。同时,作为一类有机合成中间体,菲类化合物在有机合成化学、药物化学、材料化学、电化学等领域都有广泛的应用价值。 目前,羟基取代的菲类衍生物的合成方法主要有以下两种:1)先通过二氯亚砜氯化,然后在三氯化铝的催化作用下发生傅克酰基化反应;2)以甲基磺酸作为催化剂进行催化反应。然而,这些合成方法的底物普适性非常有限,仅适用于个别9-羟基菲化合物的合成,且产率不高(Organic Letters, 2006,8, 3951-3954)。而且,使用甲基磺酸催化,通常需要加入大大过量的甲基磺酸才能促进反应的顺利进行,且在反应过程中易生成醚类、甲磺酸酯类副产物。因此,开发一种普适性好、原料简单易得、反应收率高、反应时间短、操作简单、反应条件温和的合成路线,用于合成羟基取代的菲类衍生物,具有很好的实用价值。
发明内容
本发明的目的就是为了克服上述现有技术存在的缺陷而提供一种羟基取代的菲类衍生物的合成方法。
本发明的目的可以通过以下技术方案来实现:
一种羟基取代的菲类衍生物的合成方法,所述的羟基取代的菲类衍生物是以2-羧甲基联苯类化合物为原料,在催化剂的作用下反应而成,所述的催化剂包括三氟甲磺酸或五氧化二磷中的一种或两种。
进一步地,所述的反应在有机溶剂中进行。
进一步地,所述的有机溶剂包括二氯甲烷或甲基磺酸中的一种或两种。
进一步地,所述的羟基取代的菲类衍生物的结构如式I所示:
所述的2-羧甲基联苯类化合物的结构如式II所示:
其中,R1、R2分别独立地选自氢、卤素、氰基、取代的或未取代的C1~C15烷基、取代的或未取代的C1~C15烷氧基、C1~C15卤代烷基、C1~C15卤代烷氧基、-C1~C6亚烷基-O-C1~C6亚烷基-或-C1~C6亚烷基-S-C1~C6亚烷基-。
进一步地,所述的R1及R2中,取代的C1~C15烷基为一个或多个取代基取代的C1~C15烷基,取代的C1~C15烷氧基为一个或多个取代基取代C1~C15烷氧基,所述的取代基为卤素、氰基、硝基、C1~C6烷基、C1~C6烷氧基、C1~C6卤代烷基或C1~C6卤代烷氧基。
进一步地,该合成方法包括以下步骤:
1-1)以2-羧甲基联苯类化合物为原料,在三氟甲磺酸-五氧化二磷催化作用下,以二氯甲烷为溶剂,在室温下反应1-3h;
1-2)反应结束后淬灭反应,经分离后即得到所述的羟基取代的菲类衍生物。
进一步地,步骤1-1)中,所述的2-羧甲基联苯类化合物、三氟甲磺酸、五氧化二磷的摩尔比为1:3.0~10.0:2.0~6.0,优选为1:5.0:3.0。
作为优选的技术方案,步骤1-2)具体为:反应结束后,水淬灭反应,经乙酸乙酯萃取后,旋去溶剂,再经柱层析分离后,即得到所述的羟基取代的菲类衍生物。
或者,该合成方法包括以下步骤:
2-1)以2-羧甲基联苯类化合物为原料,加入添加剂,在五氧化二磷催化作用下,以甲基磺酸为溶剂,在室温下反应1-3h;
2-2)反应结束后淬灭反应,经分离后得到酯类中间体;
2-3)将酯类中间体在碱性溶液中水解,经分离后即得到所述的羟基取代的菲类衍生物。
进一步地,步骤2-1)中,所述的添加剂包括甲酸、乙酸、苯甲酸或苯乙酸中的一种或更多种;步骤2-3)中,所述的碱性溶液为乙醇、水及氢氧化钠的混合溶液。其中,添加剂可以促使生成易水解的酯类中间体,避免不易水解的甲基磺酸酯的生成。
进一步地,步骤2-1)中,所述的2-羧甲基联苯类化合物、添加剂、五氧化二磷的摩尔比为1:1.0~3.0:2.0~6.0。甲基磺酸的用量为每摩尔原料1~8升。
作为优选的技术方案,步骤2-2)具体为:反应结束后,将反应液滴加到水和乙酸乙酯的混合溶液中淬灭,经乙酸乙酯萃取后,旋去溶剂,得到成酯的中间体产物,即酯类中间体。
作为优选的技术方案,步骤2-3)具体为:将酯类中间体加入至乙醇和水的混合溶液中,以氢氧化钠为碱,室温下水解;经乙酸乙酯萃取后,水洗、干燥并旋去溶剂,再经柱层析分离后,即得到所述的羟基取代的菲类衍生物。
作为优选的技术方案,所述的2-羧甲基联苯类化合物的合成过程如下:
以DMF:水(体积比为1:1)为溶剂,醋酸钯或氯化钯为催化剂,碳酸铯或碳酸钠为碱,邻溴苯乙酸和芳基硼酸为原料,在50~100℃下反应0.5~3h。反应结束后,用稀盐酸酸化至弱酸性,经乙酸乙酯萃取后,旋去溶剂,再经柱层析分离后,即得到所述的2-羧甲基联苯类化合物。其中,邻溴苯乙酸、芳基硼酸、催化剂、碱的摩尔比为1:1.2~2.0:0.01~0.05:1.5~6.0,优选为1:1.5:0.02:3.0。
本发明在合成羟基取代的菲类衍生物过程中,采用两种具体的合成工艺:步骤1-1)及步骤1-2)为第一种合成工艺,其利用三氟甲磺酸和五氧化二磷为催化剂,可以在室温下快速催化反应进行,以高产率顺利得到羟基取代的菲类产物,避免生成羟基菲的磺酸酯类副产物以及菲醚类副产物;步骤2-1)、步骤2-2)、步骤2-3)为第二种合成工艺,其利用羧酸作为添加剂,在室温下反应,可以避免生成不易水解的羟基菲的甲基磺酸酯,促使生成易水解的羧酸酯类中间体,随后在碱性溶液中水解,即可以较高产率获得羟基取代的菲类衍生物。
与现有技术相比,本发明合成方法具有催化剂价廉易得、官能团普适性好、操作简便、反应时间短、反应收率高、反应条件温和等优点。
具体实施方式
下面结合具体实施例对本发明进行详细说明。本实施例以本发明技术方案为前提进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。
实施例1:
2-羧甲基联苯的合成
在25mL的圆底烧瓶中加入2-溴苯乙酸(430mg,2mmol)、苯硼酸(366mg,3mmol)、醋酸钯(1mol%,4.5mg,0.02mmol)、碳酸钠(636mg,6mmol)、DMF(2mL)、水(2mL),并在油浴100℃下反应1h;反应结束后加入饱和食盐水10ml,并用稀盐酸酸化至弱酸性;用乙酸乙酯萃取(3×10mL)、减压除溶后,经柱层析纯化分离得到目标化合物2-羧甲基联苯,白色固体,产率98%,m.p.114-115℃。1H NMR(400MHz,CDCl3)δ9.76(s,1H),7.43–7.24(m,9H),3.62(s,2H);13C NMR(101MHz,CDCl3)δ178.39,142.65,140.94,131.07,130.42,130.31,129.25(2C),128.31(2C),127.63,127.45,127.30,38.57。
按照本实施例1的方法,可采用不同的起始原料,制备出不同的2-羧甲基联苯类化合物。例如:
白色固体,产率98%,m.p.116-117℃。1H NMR(400MHz,CDCl3)δ9.41(s,1H),7.38–7.15(m,8H),3.63(s,2H),2.39(s,3H).13C NMR(101MHz,CDCl3)δ178.35,142.61,137.99,136.95,131.11,130.37(2C),129.11(2C),129.00(2C),127.44,127.41,38.54,21.20。
白色固体,产率95%,m.p.108-109℃。1H NMR(400MHz,CDCl3)δ9.85(s,1H),7.37–7.20(m,6H),6.96–6.91(m,2H),3.83(s,3H),3.63(s,2H);13C NMR(101MHz,CDCl3)δ178.38,158.89,142.30,133.32,131.25,130.48,130.38,130.34(2C),127.41,127.36,113.75(2C),55.31,38.59。
白色固体,产率96%,m.p.105-106℃。1H NMR(400MHz,CDCl3)δ9.13(s,1H),7.44–7.21(m,8H),3.65(s,2H),1.36(s,9H).13C NMR(101MHz,CDCl3)δ178.38,150.11,142.56,137.88,131.12,130.42,130.34,128.92(2C),127.40,127.38,125.21(2C),38.53,34.58,31.41(3C)。
白色固体,产率99%,m.p.140-141℃。1H NMR(400MHz,CDCl3)δ9.47(s,1H),7.40–7.30(m,3H),7.30–7.23(m,3H),7.15–7.03(m,2H),3.60(s,2H).13C NMR(101MHz,CDCl3)δ178.08,162.23(d,J=246.4Hz),141.59,136.83(d,J=3.4Hz),131.14,130.89,130.81,130.46,130.37,127.82,127.52,115.32,115.11,38.52。
白色固体,产率85%,m.p.142-143℃。1H NMR(400MHz,CDCl3)δ9.03(s,1H),7.46–7.29(m,5H),7.28–7.21(m,3H),3.60(s,2H).13C NMR(101MHz,CDCl3)δ177.95,141.38,139.32,133.46,130.99,130.58(2C),130.52,130.21,128.51(2C),127.97,127.57,38.46。
白色固体,产率87%,m.p.158-159℃。1H NMR(400MHz,CDCl3)δ9.27(s,1H),7.70(d,J=8.0Hz,2H),7.47(d,J=7.9Hz,2H),7.44–7.36(m,3H),7.29(dt,J=9.0,2.5Hz,1H),3.63(s,2H).13C NMR(101MHz,CDCl3)δ177.79,144.58,141.19,130.88,130.61,130.10,129.59(d,J=32.5Hz),129.64,128.31,127.66,125.27(d,J=11.1Hz),125.27(d,J=3.7Hz),124.21(d,J=272.0Hz),38.39。
白色固体,产率95%,m.p.89-90℃。1H NMR(400MHz,CDCl3)δ10.40(s,1H),7.40–7.22(m,5H),7.16(d,J=7.6Hz,1H),7.09(d,J=7.7Hz,2H),3.62(s,2H),2.36(s,3H).13CNMR(101MHz,CDCl3)δ178.39,142.76,140.87,137.90,131.05,130.36,130.23,130.00,128.17,127.99,127.51,127.37,126.26,38.57,21.45。
白色固体,产率99%,m.p.87-88℃。1H NMR(400MHz,CDCl3)δ10.91(s,1H),7.49–7.15(m,5H),7.02–6.75(m,3H),3.78(s,3H),3.63(s,2H).13C NMR(101MHz,CDCl3)δ178.34,159.39,142.51,142.29,131.02,130.40,130.14,129.33,127.67,127.41,121.64,114.64,113.22,55.22,38.53。
白色固体,产率99%,m.p.116-117℃。1H NMR(400MHz,CDCl3)δ8.98(s,1H),7.36–7.21(m,4H),6.86–6.69(m,3H),5.98(s,2H),3.64(s,2H).13C NMR(101MHz,CDCl3)δ178.18,147.49,146.87,142.23,134.76,131.27,130.39(2C),127.55,127.41,122.66,109.84,108.18,101.11,38.53。
白色固体,产率97%,m.p.94-95℃。1H NMR(400MHz,CDCl3)δ10.21(s,1H),7.37–7.23(m,4H),6.98(s,1H),6.90(s,2H),3.62(s,2H),2.32(s,6H).13C NMR(101MHz,CDCl3)δ178.39,142.85,140.82,137.76(2C),131.03,130.30,130.17,128.84,127.40,127.30,127.05(2C),38.59,21.33(2C)。
白色固体,产率99%,m.p.125-126℃。1H NMR(400MHz,CDCl3)δ9.83(s,1H),7.40–7.26(m,4H),6.46(s,3H),3.77(s,6H),3.64(s,2H).13C NMR(101MHz,CDCl3)δ178.28,160.54(2C),142.88,142.57,130.97,130.38,129.94,127.71,127.38,107.33(2C),99.68,55.35(2C),38.50。
白色固体,产率99%,m.p.115-118℃。1H NMR(400MHz,CDCl3)δ9.13(s,1H),7.40–7.27(m,4H),6.54(s,2H),3.89(s,3H),3.82(s,6H),3.65(s,2H).13C NMR(101MHz,CDCl3)δ178.19,152.92(2C),142.60,137.15,136.45,131.06,130.41,130.09,127.68,127.43,106.48(2C),60.93,56.06(2C),38.58。
白色固体,产率97%,m.p.135-136℃。1H NMR(400MHz,CDCl3)δ9.03(s,1H),7.40–7.30(m,3H),7.26–7.11(m,3H),7.05–7.00(m,1H),3.60(s,2H).13C NMR(101MHz,CDCl3)δ177.86,151.39–150.93(m),148.83–148.44(m),140.52,137.88–137.68(m),131.05,130.58,130.19,128.23,127.63,125.42(dd,J=6.1,3.6Hz),118.36(d,J=17.3Hz),117.14(d,J=17.2Hz),38.46。
白色固体,产率96%,m.p.124-125℃。1H NMR(400MHz,CDCl3)δ8.66(s,1H),7.45–7.28(m,3H),7.28–7.20(m,1H),6.90–6.75(m,3H),3.61(s,2H).13C NMR(101MHz,CDCl3)δ177.79,163.96(d,J=13.0Hz),161.49(d,J=13.0Hz),144.09(t,J=9.5Hz),140.36(s),130.86,130.65,129.87,128.48,127.66,112.40(d,J=25.3Hz),112.40(d,J=11.3Hz),102.86(t,J=25.2Hz),38.38。
白色固体,产率96%,m.p.109-111℃。1H NMR(400MHz,CDCl3)δ8.27(s,1H),7.44–7.29(m,3H),7.22(d,J=7.2Hz,1H),7.01–6.89(m,2H),3.60(s,2H);13C NMR(101MHz,CDCl3)δ177.38,152.12(dd,J=9.9,4.2Hz),149.63(dd,J=9.9,4.2Hz),140.54(t,J=15.2Hz),139.63(t,J=2.5Hz),136.78(ddd,J=7.8,4.9,2.2Hz),130.92,130.69,129.99,128.65,127.75,113.60(d,J=21.4Hz),113.60(d,J=9.6Hz),38.35。
白色固体,产率98%,m.p.112.6-113.4℃。1H NMR(400MHz,CDCl3)δ9.99(s,1H),7.44–7.21(m,6H),6.90(dd,J=8.5,2.8Hz,1H),6.82(d,J=2.7Hz,1H),3.80(s,3H),3.54(s,2H).13C NMR(101MHz,CDCl3)δ178.52,158.58,143.80,140.96,131.49,129.10(2C),128.31(2C),127.37,123.26,115.42,113.50,55.34,37.70。
白色固体,产率95%,m.p.108.7-109.5℃。1H NMR(400MHz,CDCl3)δ10.79(s,1H),7.29–7.16(m,5H),6.88(dd,J=8.5,2.8Hz,1H),6.81(d,J=2.7Hz,1H),3.80(s,3H),3.55(s,2H),2.39(s,3H).13C NMR(101MHz,CDCl3)δ178.68,158.56,143.80,138.05,137.06,131.45,129.01(2C),128.98(2C),123.34,115.46,113.34,55.32,37.73,21.20。
白色固体,产率93%,m.p.104-105℃。1H NMR(400MHz,CDCl3)δ10.62(s,1H),7.30–7.20(m,3H),6.98–6.90(m,2H),6.87(dt,J=8.5,2.9Hz,1H),6.81(dd,J=7.6,2.7Hz,1H),3.82(d,J=13.4Hz,6H),3.55(s,2H).13C NMR(101MHz,CDCl3)δ178.63,158.93,158.55,143.46,133.33,131.43,130.20(2C),123.45,115.58,113.73(2C),113.21,55.31(2C),37.74。
白色固体,产率40%,m.p.110.8-111.7℃。1H NMR(400MHz,CDCl3)δ10.85(s,1H),7.44–7.18(m,8H),3.59(s,2H).13C NMR(101MHz,CDCl3)δ177.57,141.10,139.74,133.34,132.76,131.51,130.31,129.14(2C),128.45(2C),127.63(2C),38.32。
白色固体,产率78%,m.p.139.2-142.4℃。1H NMR(400MHz,CDCl3)δ10.03(s,1H),7.41–7.10(m,5H),6.94(d,J=3.8Hz,2H),3.84(s,3H),3.60(s,2H);13C NMR(101MHz,CDCl3)δ177.57,159.13,140.78,133.03,132.93,132.06,131.68,130.27(3C),127.58,113.88(2C),55.33,38.36。
白色固体,产率99%,m.p.118.1-119℃。1H NMR(400MHz,CDCl3)δ10.22(s,1H),7.44–7.33(m,3H),7.30–7.20(m,3H),7.13–6.99(m,2H),3.60(s,2H);13C NMR(101MHz,CDCl3)δ177.56,161.97(d,J=246.4Hz),139.94,138.64(d,J=3.2Hz),133.03(d,J=7.9Hz),131.75(d,J=8.1Hz),129.32,128.40,127.46,117.10,116.88,114.54,114.33,38.49(d,J=1.4Hz)。
白色固体,产率98%,m.p.102.4-102.9℃。1H NMR(400MHz,CDCl3)δ11.09(s,1H),7.28–6.97(m,7H),3.60(s,2H),2.39(s,3H).13C NMR(101MHz,CDCl3)δ177.85,161.87(d,J=246.2Hz),138.63(d,J=3.2Hz),137.18,137.00,133.07(d,J=7.8Hz),131.80(d,J=8.1Hz),129.19(2C),129.10(2C),116.93(d,J=21.8Hz),114.40(d,J=20.9Hz),38.54,21.17。
白色固体,产率97%,m.p.93.2-94.0℃。1H NMR(400MHz,CDCl3)δ10.52(s,1H),7.20(tt,J=5.0,4.4Hz,3H),7.11–6.98(m,2H),6.97–6.91(m,2H),3.84(s,3H),3.61(s,2H).13C NMR(101MHz,CDCl3)δ177.67,161.82(d,J=246.1Hz),159.00,138.31(d,J=3.2Hz),133.19(d,J=7.9Hz),132.28,131.89(d,J=8.1Hz),130.42(2C),116.92(d,J=21.8Hz),114.38(d,J=20.9Hz),113.82(2C),55.31,38.54。
白色固体,产率99%,m.p.119.7-120.6℃。1H NMR(400MHz,CDCl3)δ10.42(s,1H),7.44–7.23(m,6H),7.09–6.96(m,2H),3.58(s,2H).13C NMR(101MHz,CDCl3)δ178.07,161.69(d,J=246.9Hz),144.56(d,J=7.8Hz),139.88(d,J=1.6Hz),132.01(d,J=8.3Hz),128.97,128.45,127.74,126.84(d,J=3.3Hz),117.09,116.88,114.65,114.44,37.73。
白色固体,产率92%,m.p.126.6-128℃。1H NMR(400MHz,CDCl3)δ10.11(s,1H),7.31(d,J=5.3Hz,1H),7.19(d,J=13.7Hz,4H),7.00(dd,J=16.4,5.7Hz,2H),3.58(s,2H),2.39(s,3H).13C NMR(101MHz,CDCl3)δ178.19,161.68(d,J=246.8Hz),144.59(d,J=7.8Hz),137.49,136.98(d,J=1.7Hz),131.95(d,J=8.4Hz),129.14,128.85,126.90(d,J=3.3Hz),117.12,116.90,114.45,114.24,37.75,21.19。
白色固体,产率94%,m.p.112.4-113.7℃。1H NMR(400MHz,CDCl3)δ10.04(s,1H),7.36–7.16(m,3H),7.08–6.86(m,4H),3.84(s,3H),3.59(s,2H);13C NMR(101MHz,CDCl3)δ178.17,161.68(d,J=246.8Hz),159.19,144.27(d,J=7.9Hz),132.27(d,J=1.7Hz),131.95(d,J=8.4Hz),130.14(2C),127.04(d,J=3.2Hz),117.09(d,J=21.2Hz),114.26(d,J=21.2Hz),113.88(2C),55.32,37.79。
实施例2:
9-羟基菲的合成
在10mL的圆底烧瓶中,向2-羧甲基联苯(106mg,0.5mmol)和五氧化二磷(213mg,1.5mmol)的二氯甲烷(2mL)溶液中加入三氟甲磺酸(375mg,2.5mmol),室温搅拌下反应2h;反应结束后,将反应液滴加到水(10mL)和乙酸乙酯(10mL)的混合溶液中淬灭;然后用乙酸乙酯萃取(3×10mL),旋去溶剂,经柱层析纯化分离得到目标化合物9-羟基菲,白色固体,产率91%,m.p.150-151℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,CDCl3)δ149.50,132.68,131.58,127.26,126.98,126.76(2C),126.45,125.56,124.32,122.74,122.61,122.36,106.14;HRMS(EI)calcd forC14H10O[M]+194.0732,found 194.0733.
实施例3:
9-羟基菲的合成
在10mL的圆底烧瓶中,向2-羧甲基联苯(106mg,0.5mmol)、五氧化二磷(282mg,2mmol)、苯乙酸(102mg,0.75mmol)中加入甲基磺酸(2mL),室温搅拌下反应2h;反应结束后,将反应液滴加到水(10mL)和乙酸乙酯(10mL)的混合溶液中淬灭;然后用乙酸乙酯萃取(3×10mL),减压去溶剂后置于10mL的圆底烧瓶中,加入氢氧化钠(100mg,25mmol)、水(1mL)和乙醇(1mL),室温搅拌2小时,反应结束后加入饱和食盐水10mL,用乙酸乙酯萃取(3×10mL),旋去溶剂,经柱层析纯化分离得到目标化合物9-羟基菲的合成,产率84%,表征数据如实施例2。
按照实施例2或实施例3的方法,可采用不同的2-羧甲基联苯类化合物为起始原料,制备不同的羟基取代的菲类衍生物。例如:
白色固体,m.p.131-132℃。1H NMR(400MHz,CDCl3)δ8.54(dd,J=8.8,5.3Hz,2H),8.08(s,1H),7.72–7.63(m,1H),7.59–7.40(m,3H),6.97(s,1H),5.36(s,1H),2.58(s,3H).13C NMR(101MHz,CDCl3)δ149.32,136.33,132.27,129.45,128.97,126.82,126.69,126.53,125.59,124.24,122.70,122.39,121.85,106.15,21.71;HRMS(EI)calcd forC15H12O[M]+208.0888,found 208.0886.
白色固体,m.p.121-122℃。1H NMR(400MHz,CDCl3)δ8.54(d,J=9.1Hz,1H),8.47(dd,J=8.6,4.3Hz,1H),7.72–7.58(m,2H),7.52–7.40(m,2H),7.30(dd,J=9.1,2.7Hz,1H),6.95(s,1H),5.53(s,1H),3.96(s,3H).13C NMR(101MHz,CDCl3)δ158.33,149.11,131.54,126.91,126.82,126.72,125.99,125.92,124.44,124.38,122.08,117.84,106.64,102.76,55.52;HRMS(EI)calcd for C15H12O2[M]+224.0837,found 224.0836.
白色固体,m.p.114-115℃。1H NMR(400MHz,CDCl3)δ8.68–8.41(m,2H),8.40–8.23(m,1H),7.83–7.41(m,4H),6.94(d,J=6.0Hz,1H),5.75–5.46(m,1H),1.46(s,9H).13C NMR(101MHz,CDCl3)δ149.77,149.45,132.44,129.43,126.71,126.66,126.53,125.52,125.36,124.16,122.59,122.45,117.97,106.06,35.07,31.48(2C),31.43;HRMS(EI)calcdfor C18H18O[M]+250.1358,found 250.1355.
白色固体,m.p.161-164℃。1H NMR(400MHz,DMSO)δ10.53(s,1H),8.86(dd,J=9.1,5.5Hz,1H),8.65(d,J=8.1Hz,1H),7.93(dd,J=10.4,2.7Hz,1H),7.78(d,J=7.6Hz,1H),7.63–7.43(m,3H),7.17(s,1H).13C NMR(101MHz,DMSO)δ160.71(d,J=243.7Hz),150.26(d,J=3.6Hz),132.47,127.84(d,J=1.7Hz),127.59(d,J=8.4Hz),126.77,126.55,125.90(d,J=8.7Hz),125.04,123.92,122.62,115.70(d,J=23.5Hz),106.89(d,J=22.1Hz),105.99;HRMS(EI)calcd for C14H9F1O[M]+212.0637,found 212.0638.
白色固体,m.p.149-150℃。1H NMR(400MHz,DMSO)δ10.58(s,1H),8.83(dd,J=14.8,8.9Hz,1H),8.67(t,J=10.8Hz,1H),8.25(d,J=2.3Hz,1H),7.82–7.67(m,2H),7.59–7.52(m,1H),7.51–7.44(m,1H),7.16(d,J=4.5Hz,1H).13C NMR(101MHz,DMSO)δ149.94,132.93,131.20,129.54,127.27,127.24,127.09,126.59,125.30,124.81,123.98,122.77,121.51,106.15;HRMS(EI)calcd for C14H9 35ClO[M]+228.0342,found 228.0345,calcd forC14H9 37ClO[M]+230.0312,found 230.0318.
白色固体,m.p.157-158℃。1H NMR(400MHz,DMSO)δ10.79(s,1H),9.02(d,J=8.7Hz,1H),8.76(d,J=8.2Hz,1H),8.60(s,1H),7.97(dd,J=8.7,1.4Hz,1H),7.84(t,J=7.9Hz,1H),7.58(dt,J=38.5,7.2Hz,2H),7.25(s,1H).13C NMR(101MHz,DMSO)δ150.63,133.90,133.30,128.14,126.70,126.39(d,J=31.9Hz),125.90(d,J=2.8Hz),125.50,124.49,124.13,123.35,122.48(d,J=3.3Hz),119.71(d,J=4.3Hz),106.34;HRMS(EI)calcd for C15H9F3O[M]+262.0605,found 262.0602.
白色固体,m.p.149-150℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ151.11,136.41,133.22,131.11,127.80,126.70,126.33,125.07,124.01,123.24,122.60,122.43(2C),103.98,21.51;HRMS(EI)calcd for C15H12O[M]+208.0888,found 208.0887.
白色固体,m.p.110-112℃。1H NMR(400MHz,DMSO)δ10.24(s,1H),8.67(d,J=8.2Hz,1H),8.18(dd,J=16.9,5.1Hz,2H),7.71(d,J=7.9Hz,1H),7.50(t,J=7.4Hz,1H),7.41(t,J=7.6Hz,1H),7.29(dd,J=8.9,1.7Hz,1H),6.95(s,1H),4.00(s,3H).13C NMR(101MHz,DMSO)δ158.55,151.15,133.65,132.72,126.89,126.32,124.88,124.17,123.03,122.95,120.46,116.14,104.19,102.74,55.40;HRMS(EI)calcd for C15H12O2[M]+224.0837,found 224.0838.
白色固体,m.p.140.3-141℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ150.70,148.17,147.14,132.34,127.44,126.29,125.91,125.19,123.09,122.66,121.97,103.74,101.42,101.20,99.90;HRMS(EI)calcd for C15H10O3[M]+238.0630,found 238.0629.
白色固体,m.p.153-154℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ153.87,135.65,135.25,132.93,132.74,131.46,126.65,125.59,125.34,123.02(2C),122.98,120.77,105.12,24.89,21.16;HRMS(EI)calcd for C16H14O[M]+222.1045,found 222.1044.
白色固体,m.p.143-144℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ158.81,157.52,151.76,134.33,133.69,127.32,126.20,124.30,123.61,123.16,109.87,104.61,98.83,97.53,56.66,55.55;HRMS(EI)calcd for C16H14O3[M]+254.0943,found 254.0942.
黄色油状,产率88%。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ152.93,151.08,149.00,140.98,132.84,128.82,126.80,126.21,124.43,123.35,123.21,113.24,105.16,101.19,62.49,60.76,56.05;HRMS(EI)calcd for C17H16O4[M]+284.1049,found 284.1048.
白色固体,m.p.165-166℃。1H NMR(400MHz,DMSO)δ10.62(s,1H),8.85(dd,J=13.0,8.0Hz,1H),8.64(d,J=8.2Hz,1H),8.11(dd,J=11.9,8.6Hz,1H),7.79(d,J=7.6Hz,1H),7.60–7.42(m,2H),7.15(s,1H).13C NMR(101MHz,DMSO)δ151.32–150.28(m),150.49(dd,J=3.2,1.6Hz),148.36(dd,J=74.4,14.2Hz),133.57,129.12(dd,J=7.0,2.2Hz),127.80,127.08,125.08–124.93(m),124.32,123.83(dd,J=6.6,1.6Hz),123.73,111.70(d,J=18.2Hz),110.21(d,J=17.9Hz),105.92(d,J=1.9Hz);HRMS(EI)calcd forC14H8F2O[M]+230.0543,found 230.0540.
白色固体,m.p.153-154℃。1H NMR(400MHz,CDCl3)δ8.35(d,J=8.3Hz,1H),8.21–8.07(m,1H),7.80–7.67(m,1H),7.65–7.53(m,1H),7.48(ddd,J=8.3,7.0,1.3Hz,1H),7.18–7.04(m,2H),6.72(s,1H).13C NMR(101MHz,CDCl3)δ161.43(dd,J=56.3,14.3Hz),158.98(dd,J=53.0,14.1Hz),148.34,134.93(dd,J=9.5,4.6Hz),133.81,128.42,127.23,124.72,123.02,1108.63(t,J=2.6Hz),105.36(d,J=3.9Hz),105.14(d,J=3.9Hz),102.48(d,J=56.1Hz),102.20;HRMS(EI)calcd for C14H8F2O[M]+230.0543,found230.0542.
白色固体,m.p.114-117℃。1H NMR(400MHz,DMSO)δ10.50(s,1H),8.69(ddd,J=34.2,18.4,4.8Hz,2H),7.76(d,J=7.8Hz,1H),7.58(t,J=7.4Hz,1H),7.53–7.42(m,1H),7.13(s,1H).13C NMR(101MHz,DMSO)δ150.67–148.24(m),150.02(dd,J=5.6,3.8Hz),146.95(ddd,J=226.0,11.0,3.5Hz),137.93(dt,J=33.0,15.3Hz),132.91,128.47–128.26(m),127.98,126.36,124.24,123.72–123.34(m),113.18(dd,J=6.1,2.1Hz),107.08,106.04(d,J=4.4Hz),105.86(d,J=4.3Hz);HRMS(EI)calcd for C14H7F3O[M]+248.0449,found 248.045.
白色固体,m.p.143.8-144.5℃。1H NMR(400MHz,DMSO)δ10.06(s,1H),8.83–8.75(m,1H),8.30–8.23(m,1H),8.11(d,J=2.4Hz,1H),7.71–7.61(m,3H),7.19(dd,J=8.7,2.5Hz,1H),7.06(s,1H),3.94(d,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ161.33,154.35,135.66,133.02,132.52,131.77,131.61,131.56,131.46,128.42,127.68,122.30,110.05,109.49,60.59;HRMS(EI)calcd for C15H12O2[M]+224.0837,found 224.0836.
白色固体,m.p.125.9-126℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ156.05,148.92,135.51,128.36,128.13,127.68,126.87,126.43,126.39,123.15,121.95,116.60,104.82,104.00,55.30,21.28;HRMS(EI)calcd for C16H14O2[M]+238.0994,found 238.0995.
白色固体,m.p.127.2-128℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ157.84,156.17,148.62,127.71(2C),126.54,126.10,125.01,124.71,116.77,116.00,105.33,103.73,102.73,55.29,55.13;HRMS(EI)calcd for C16H14O3[M]+254.0943,found 254.0942.
白色固体,产率96%,m.p.134.8-135.6℃。1H NMR(400MHz,DMSO)δ10.61(s,1H),8.72(dd,J=25.8,8.3Hz,2H),8.30(dd,J=8.0,1.4Hz,1H),7.89(d,J=2.2Hz,1H),7.71(dtd,J=14.7,7.0,1.3Hz,2H),7.44(dd,J=8.8,2.3Hz,1H),7.10(s,1H).13C NMR(101MHz,DMSO)δ152.25,134.43,131.49,130.58,127.50,126.60,126.01,125.04,124.85,123.80,123.39,122.94,122.61,103.92;HRMS(EI)calcd for C14H9 35ClO[M]+228.0342,found228.0345,calcd for C14H9 37ClO[M]+230.0312,found 230.0318.
白色固体,m.p.153.8-154.5℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ158.07,151.74,133.20,130.36,127.45,124.96,124.79,124.77,124.24,123.96,123.42,117.67,104.41,103.00,55.20;HRMS(EI)calcd for C15H11 35ClO2[M]+258.0448,found 258.0445,calcd forC15H11 37ClO2[M]+260.0418,found 260.0420.
白色固体,m.p.133.8-134.6℃。1H NMR(400MHz,DMSO)δ10.57(s,1H),8.72(dd,J=8.8,5.9Hz,2H),8.30(dd,J=8.1,1.2Hz,1H),7.75–7.56(m,3H),7.29(td,J=8.8,2.7Hz,1H),7.11(s,1H).13C NMR(101MHz,DMSO)δ161.09(d,J=242.9Hz),152.24,134.75(d,J=9.6Hz),130.79,127.43,126.07,125.56(d,J=0.9Hz),125.37(d,J=9.3Hz),122.80,122.60,122.09(d,J=1.6Hz),111.89(d,J=23.5Hz),110.34(d,J=21.0Hz),104.33(d,J=3.6Hz);HRMS(EI)calcd for C14H9FO[M]+212.0637,found212.0639.
白色固体,m.p.149.9-151.5℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ160.83(d,J=242.4Hz),152.09,135.38,134.28(d,J=9.5Hz),129.02,128.71,125.63,125.05(d,J=9.2Hz),122.78,122.17(d,J=1.5Hz),122.09,111.77(d,J=23.5Hz),110.24(d,J=20.9Hz),104.34(d,J=3.5Hz),21.19;HRMS(EI)calcd for C15H11FO[M]+226.0794,found 226.0796.
白色固体,m.p.152.5-152.8℃。1H NMR(400MHz,DMSO)δ10.55(s,1H),8.67–8.57(m,2H),7.67(d,J=2.8Hz,1H),7.56(dd,J=10.4,2.7Hz,1H),7.35–7.22(m,2H),7.11(s,1H),3.93(s,3H).13C NMR(101MHz,DMSO)δ160.47(d,J=241.7Hz),157.67,151.77,133.38(d,J=9.4Hz),126.92,125.05,124.72,124.62,122.26(d,J=1.4Hz),117.62,111.91(d,J=23.6Hz),110.24(d,J=20.9Hz),104.82(d,J=3.6Hz),102.97,55.16;HRMS(EI)calcdfor C15H11FO2[M]+242.0743,found 242.0744.
白色固体,m.p.151.5-152℃。1H NMR(400MHz,DMSO)δ10.36(s,1H),8.83–8.72(m,1H),8.50(dd,J=11.6,2.5Hz,1H),8.37–8.25(m,1H),7.83(dd,J=8.8,6.0Hz,1H),7.77–7.64(m,2H),7.42(td,J=8.6,2.6Hz,1H),7.14(s,1H).13C NMR(101MHz,DMSO)δ159.23(d,J=239.2Hz),150.49(d,J=2.3Hz),130.41(d,J=4.3Hz),129.72(d,J=1.2Hz),128.50(d,J=8.5Hz),127.04,126.85,126.44(d,J=8.2Hz),126.35,123.37,122.52,115.59(d,J=23.7Hz),107.77(d,J=22.2Hz),104.40;HRMS(EI)calcd for C14H9FO[M]+212.0637,found212.0638.
白色固体,m.p.144-144.4℃。1H NMR(400MHz,CDCl3)δ8.38(d,J=8.5Hz,1H),8.14(dd,J=11.2,2.5Hz,1H),8.07(s,1H),7.60(dd,J=8.8,5.8Hz,1H),7.49(dd,J=8.5,1.7Hz,1H),7.24(td,J=8.4,2.5Hz,1H),6.93(s,1H),5.23(s,1H),2.57(s,3H).13C NMR(101MHz,DMSO)δ160.83(d,J=242.4Hz),152.09,135.38,134.28(d,J=9.5Hz),129.02,128.71,125.63(d,J=0.9Hz),125.05(d,J=9.2Hz),122.78,122.17(d,J=1.5Hz),122.09,111.77(d,J=23.5Hz),110.24(d,J=20.9Hz),104.34(d,J=3.5Hz),21.19;HRMS(EI)calcd for C15H11FO[M]+226.0794,found 226.0796.
白色固体,m.p.120.2-121.5℃。1H NMR(400MHz,CDCl3)δ8.67(dd,J=8.4,0.8Hz,1H),8.58(dd,J=8.4,6.7Hz,1H),8.31(dd,J=8.0,1.2Hz,1H),7.79–7.60(m,3H),7.60–7.45(m,2H),6.99(s,1H),5.21(s,1H).13C NMR(101MHz,DMSO)δ159.33(d,J=239.0Hz),158.28,149.98(d,J=2.3Hz),128.57–128.43(m),128.38,127.84,126.61(d,J=8.3Hz),125.24,124.65(d,J=4.3Hz),117.22,114.49(d,J=23.7Hz),107.16(d,J=22.3Hz),104.89,102.88,55.19;HRMS(EI)calcd for C15H11FO2[M]+242.0743,found 242.0742.
实施例4:
一种羟基取代的菲类衍生物的合成方法,该方法为:以2-羧甲基联苯类化合物为原料,在催化剂的作用下反应合成羟基取代的菲类衍生物,反应在有机溶剂中进行。
其中,催化剂为三氟甲磺酸。有机溶剂为二氯甲烷。
羟基取代的菲类衍生物的结构如式I所示:
2-羧甲基联苯类化合物的结构如式II所示:
其中,R1为氢,R2为卤素。
实施例5:
本实施例中,催化剂为五氧化二磷中。有机溶剂为甲基磺酸。R1为氰基,R2为一个卤素取代的C3烷基。其余同实施例4。
实施例6:
本实施例中,催化剂包括三氟甲磺酸及五氧化二磷。有机溶剂包括二氯甲烷及甲基磺酸。R1为C1烷基,R2为C15烷基。其余同实施例4。
实施例7:
本实施例中,R1为两个氰基取代的C2烷基,R2为一个硝基取代的C10烷基。其余同实施例4。
实施例8:
本实施例中,R1为C6烷基取代的C15烷氧基,R2为C1烷基取代的C3烷氧基。其余同实施例4。
实施例9:
本实施例中,R1为C1卤代烷基取代的C5烷氧基,R2为C6卤代烷氧基取代的C12烷氧基。其余同实施例4。
实施例10:
本实施例中,R1为C10烷氧基,R2为C3卤代烷基。其余同实施例4。
实施例11:
本实施例中,R1为C5卤代烷氧基,R2为-C1亚烷基-O-C3亚烷基-。其余同实施例4。
实施例12:
本实施例中,R1为-C2亚烷基-S-C4亚烷基-,R2为C1烷基。其余同实施例4。
实施例13:
一种羟基取代的菲类衍生物的合成方法,该合成方法包括以下步骤:
1-1)以2-羧甲基联苯类化合物为原料,在三氟甲磺酸-五氧化二磷催化作用下,以二氯甲烷为溶剂,在室温下反应1h,其中,2-羧甲基联苯类化合物、三氟甲磺酸、五氧化二磷的摩尔比为1:10.0:2.0;
1-2)反应结束后淬灭反应,经分离后即得到羟基取代的菲类衍生物。
实施例14:
一种羟基取代的菲类衍生物的合成方法,该合成方法包括以下步骤:
1-1)以2-羧甲基联苯类化合物为原料,在三氟甲磺酸-五氧化二磷催化作用下,以二氯甲烷为溶剂,在室温下反应3h,其中,2-羧甲基联苯类化合物、三氟甲磺酸、五氧化二磷的摩尔比为1:3.0:6.0;
1-2)反应结束后淬灭反应,经分离后即得到羟基取代的菲类衍生物。
实施例15:
一种羟基取代的菲类衍生物的合成方法,该合成方法包括以下步骤:
1-1)以2-羧甲基联苯类化合物为原料,在三氟甲磺酸-五氧化二磷催化作用下,以二氯甲烷为溶剂,在室温下反应2h,其中,2-羧甲基联苯类化合物、三氟甲磺酸、五氧化二磷的摩尔比为1:7.0:4.0;
1-2)反应结束后淬灭反应,经分离后即得到羟基取代的菲类衍生物。
实施例16:
一种羟基取代的菲类衍生物的合成方法,该合成方法包括以下步骤:
2-1)以2-羧甲基联苯类化合物为原料,加入添加剂,在五氧化二磷催化作用下,以甲基磺酸为溶剂,在室温下反应1h,其中,添加剂为苯乙酸,2-羧甲基联苯类化合物、添加剂、五氧化二磷的摩尔比为1:3.0:2.0;
2-2)反应结束后淬灭反应,经分离后得到酯类中间体;
2-3)将酯类中间体在碱性溶液中水解,经分离后即得到羟基取代的菲类衍生物,其中,碱性溶液为乙醇、水及氢氧化钠的混合溶液。
实施例17:
一种羟基取代的菲类衍生物的合成方法,该合成方法包括以下步骤:
2-1)以2-羧甲基联苯类化合物为原料,加入添加剂,在五氧化二磷催化作用下,以甲基磺酸为溶剂,在室温下反应3h,其中,添加剂包括甲酸及乙酸,2-羧甲基联苯类化合物、添加剂、五氧化二磷的摩尔比为1:1.0:6.0;
2-2)反应结束后淬灭反应,经分离后得到酯类中间体;
2-3)将酯类中间体在碱性溶液中水解,经分离后即得到羟基取代的菲类衍生物,其中,碱性溶液为乙醇、水及氢氧化钠的混合溶液。
实施例18:
一种羟基取代的菲类衍生物的合成方法,该合成方法包括以下步骤:
2-1)以2-羧甲基联苯类化合物为原料,加入添加剂,在五氧化二磷催化作用下,以甲基磺酸为溶剂,在室温下反应2h,其中,添加剂为苯甲酸,2-羧甲基联苯类化合物、添加剂、五氧化二磷的摩尔比为1:2.0:4.0;
2-2)反应结束后淬灭反应,经分离后得到酯类中间体;
2-3)将酯类中间体在碱性溶液中水解,经分离后即得到羟基取代的菲类衍生物,其中,碱性溶液为乙醇、水及氢氧化钠的混合溶液。
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。

Claims (10)

1.一种羟基取代的菲类衍生物的合成方法,其特征在于,所述的羟基取代的菲类衍生物是以2-羧甲基联苯类化合物为原料,在催化剂的作用下反应而成,所述的催化剂包括三氟甲磺酸或五氧化二磷中的一种或两种。
2.根据权利要求1所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,所述的反应在有机溶剂中进行。
3.根据权利要求2所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,所述的有机溶剂包括二氯甲烷或甲基磺酸中的一种或两种。
4.根据权利要求1所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,所述的羟基取代的菲类衍生物的结构如式I所示:
所述的2-羧甲基联苯类化合物的结构如式II所示:
其中,R1、R2分别独立地选自氢、卤素、氰基、取代的或未取代的C1~C15烷基、取代的或未取代的C1~C15烷氧基、C1~C15卤代烷基、C1~C15卤代烷氧基、-C1~C6亚烷基-O-C1~C6亚烷基-或-C1~C6亚烷基-S-C1~C6亚烷基-。
5.根据权利要求4所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,所述的R1及R2中,取代的C1~C15烷基为一个或多个取代基取代的C1~C15烷基,取代的C1~C15烷氧基为一个或多个取代基取代C1~C15烷氧基,所述的取代基为卤素、氰基、硝基、C1~C6烷基、C1~C6烷氧基、C1~C6卤代烷基或C1~C6卤代烷氧基。
6.根据权利要求1所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,该合成方法包括以下步骤:
1-1)以2-羧甲基联苯类化合物为原料,在三氟甲磺酸-五氧化二磷催化作用下,以二氯甲烷为溶剂,在室温下反应1-3h;
1-2)反应结束后淬灭反应,经分离后即得到所述的羟基取代的菲类衍生物。
7.根据权利要求6所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,步骤1-1)中,所述的2-羧甲基联苯类化合物、三氟甲磺酸、五氧化二磷的摩尔比为1:3.0~10.0:2.0~6.0。
8.根据权利要求1所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,该合成方法包括以下步骤:
2-1)以2-羧甲基联苯类化合物为原料,加入添加剂,在五氧化二磷催化作用下,以甲基磺酸为溶剂,在室温下反应1-3h;
2-2)反应结束后淬灭反应,经分离后得到酯类中间体;
2-3)将酯类中间体在碱性溶液中水解,经分离后即得到所述的羟基取代的菲类衍生物。
9.根据权利要求8所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,步骤2-1)中,所述的添加剂包括甲酸、乙酸、苯甲酸或苯乙酸中的一种或更多种;步骤2-3)中,所述的碱性溶液为乙醇、水及氢氧化钠的混合溶液。
10.根据权利要求8所述的一种羟基取代的菲类衍生物的合成方法,其特征在于,步骤2-1)中,所述的2-羧甲基联苯类化合物、添加剂、五氧化二磷的摩尔比为1:1.0~3.0:2.0~6.0。
CN201910044311.0A 2019-01-17 2019-01-17 一种羟基取代的菲类衍生物的合成方法 Expired - Fee Related CN109574809B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910044311.0A CN109574809B (zh) 2019-01-17 2019-01-17 一种羟基取代的菲类衍生物的合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910044311.0A CN109574809B (zh) 2019-01-17 2019-01-17 一种羟基取代的菲类衍生物的合成方法

Publications (2)

Publication Number Publication Date
CN109574809A true CN109574809A (zh) 2019-04-05
CN109574809B CN109574809B (zh) 2020-07-03

Family

ID=65915272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910044311.0A Expired - Fee Related CN109574809B (zh) 2019-01-17 2019-01-17 一种羟基取代的菲类衍生物的合成方法

Country Status (1)

Country Link
CN (1) CN109574809B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110437119A (zh) * 2019-09-05 2019-11-12 华东理工大学 一种n-取代含氮杂环衍生物及其制备方法与应用
CN113024365A (zh) * 2021-03-12 2021-06-25 西安瑞联新材料股份有限公司 一种苯并[c]菲-5-三氟甲磺酸酯的工业化生产方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110698380B (zh) * 2019-10-24 2021-01-15 华东理工大学 一种内酰胺衍生物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095753A1 (en) * 2006-02-24 2007-08-30 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095753A1 (en) * 2006-02-24 2007-08-30 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANHUI WU等: "Synthesis of 13 C4-labelled oxidized metabolites of the carcinogenic polycyclic aromatic hydrocarbon benzo[α]pyrene", 《TETRAHEDRON》 *
ARUN K. SHARMA等: "Synthesis, Microsome-Mediated Metabolism, and Identification of", 《CHEM. RES. TOXICOL.》 *
HASHIM F. MOTIWALA等: "Intramolecular Friedel−Crafts Acylation Reaction Promoted by", 《ORGANIC LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110437119A (zh) * 2019-09-05 2019-11-12 华东理工大学 一种n-取代含氮杂环衍生物及其制备方法与应用
CN113024365A (zh) * 2021-03-12 2021-06-25 西安瑞联新材料股份有限公司 一种苯并[c]菲-5-三氟甲磺酸酯的工业化生产方法

Also Published As

Publication number Publication date
CN109574809B (zh) 2020-07-03

Similar Documents

Publication Publication Date Title
CN109574809A (zh) 一种羟基取代的菲类衍生物的合成方法
CN107141248B (zh) 一种可见光催化合成3-砜基螺环三烯酮化合物的方法
Zhou et al. Metal-free radical oxidative cyclization of o-azidoaryl acetylenic ketones with sulfinic acids to access sulfone-containing 4-quinolones
CN107382884A (zh) 一种β‑碘代‑N‑烷氧基苯并三氮唑类化合物的合成方法
Yokosaka et al. Construction of Divergent Fused Heterocycles via an Acid-Promoted Intramolecular ipso-Friedel–Crafts Alkylation of Phenol Derivatives
Britton et al. Discovery and development of an efficient process to atovaquone
Vijender et al. Amberlist-15 as heterogeneous reusable catalyst for regioselective ring opening of epoxides with amines under mild conditions
CN101235024A (zh) 一类苯并二氢吡喃类化合物、合成方法和用途
Saidachary et al. A facile approach for the synthesis of novel substituted 4H-chromenes and condensation reactions of 4H-chromenes leading to chromenopyrrolones and triazolylchromenopyrrolones
Nandy et al. Chemoselective and metal-free synthesis of aryl esters from the corresponding benzylic alcohols in aqueous medium using TBHP/TBAI as an efficient catalytic system
CN112961041B (zh) 儿茶酚类化合物及其制备方法和应用
Hammann et al. A Transition‐Metal‐Free Synthesis of Fluorinated Naphthols
CN105949118A (zh) 一种2-芳基喹啉衍生物的制备方法
CN105153083A (zh) 一种多取代呋喃化合物的制备方法
CN108864160A (zh) 含硼小分子的制备方法
Venkateswarlu et al. Straightforward synthesis of 2-propylquinolines under multicomponent conditions in fluorinated alcohols
CN102863399A (zh) 一种靛红酸酐衍生物的合成方法
CN105294415A (zh) 一种3-卤代芴酮类化合物的制备方法
CN106588787B (zh) 一种含芳甲酰基1,2,3-三氮唑类配体的应用
CN106146271B (zh) 一种由芳基磺酸酯制备二芳基甲酮的方法
US6271418B1 (en) Process for preparing (hetero) aromatic substituted benzene derivatives
CN102516162A (zh) 铜催化的硝基芳(杂)环化合物的制备方法
CN107011251B (zh) 一种2-(2-氯苯氧基)吡啶化合物的合成方法及其用途
CN104860881A (zh) 8-(硝基甲基)喹啉类化合物和8-甲氨基四氢喹啉类化合物的合成方法
CN108047114B (zh) 卤代三氟甲基吡咯衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200703

Termination date: 20220117

CF01 Termination of patent right due to non-payment of annual fee